Roivant Sciences Ltd. Common Shares
Here’s whether Roivant Sciences Ltd. Common Shares (ROIV) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+4.89% over 10 days); strong 1-year return of +197.7%; 3-month momentum positive (+29.0%). Concerns: RSI 79 — overbought, elevated pullback risk; declining volume on rally — weak conviction (0.80x 30d avg). Currently 1.6% off its 52-week high. Score: +4/7.
ROIV is in a confirmed uptrend, trading above both its 50-day ($27.92) and 200-day ($19.77) moving averages. With an RSI of 79.4, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +197.7% compares to +35.1% for SPY (beat the market by 162.6%).